Annual Drug Patent Expirations for STEGLUJAN
Steglujan is a drug marketed by Merck Sharp Dohme and is included in one NDA. It is available from one supplier. There are five patents protecting this drug.
Drug patent litigation for STEGLUJAN.
This drug has one hundred and ninety-three patent family members in fifty-four countries.
The generic ingredient in STEGLUJAN is ertugliflozin; sitagliptin phosphate. One supplier is listed for this compound. Additional details are available on the ertugliflozin; sitagliptin phosphate profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com